Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $64.29

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has received a consensus rating of “Buy” from the nine brokerages that are covering the company, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $64.29.

Several equities research analysts recently weighed in on the stock. TD Cowen assumed coverage on shares of Jasper Therapeutics in a research note on Monday, March 18th. They issued an “outperform” rating for the company. Royal Bank of Canada assumed coverage on shares of Jasper Therapeutics in a research note on Thursday, March 28th. They issued an “outperform” rating and a $70.00 target price for the company. Evercore ISI assumed coverage on shares of Jasper Therapeutics in a research report on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research report on Wednesday, May 15th. Finally, Oppenheimer reissued an “outperform” rating and issued a $80.00 price target on shares of Jasper Therapeutics in a research report on Thursday, March 7th.

Jasper Therapeutics Price Performance

JSPR stock opened at $23.92 on Tuesday. Jasper Therapeutics has a 52-week low of $4.00 and a 52-week high of $31.01. The company has a 50-day moving average of $24.89 and a two-hundred day moving average of $16.53. The stock has a market capitalization of $360.24 million, a price-to-earnings ratio of -4.25 and a beta of 2.25.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Monday, March 4th. The company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.15. Equities analysts expect that Jasper Therapeutics will post -4.35 EPS for the current fiscal year.

Institutional Trading of Jasper Therapeutics

Several hedge funds have recently modified their holdings of the company. Opaleye Management Inc. acquired a new stake in shares of Jasper Therapeutics during the fourth quarter worth approximately $3,144,000. Kingdon Capital Management L.L.C. increased its holdings in shares of Jasper Therapeutics by 16.4% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock worth $2,793,000 after buying an additional 500,000 shares in the last quarter. Fernwood Investment Management LLC increased its holdings in shares of Jasper Therapeutics by 8.8% during the fourth quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock worth $390,000 after buying an additional 40,000 shares in the last quarter. Monaco Asset Management SAM acquired a new stake in shares of Jasper Therapeutics during the fourth quarter worth approximately $197,000. Finally, Cowen AND Company LLC acquired a new stake in shares of Jasper Therapeutics during the third quarter worth approximately $140,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.